1. Home
  2. News Archive

More News

Patients Satisfied with Same-Day Bilateral Cataract Surgery, Study Finds
Patients Satisfied with Same-Day Bilateral Cataract Surgery, Study Finds

Danish researchers who interviewed same-day bilateral cataract surgery patients found that the patients appreciated the convenience and welcomed empathetic communication before, during, and after t...

Video Series from World Council of Optometry and Alcon Summarizes TFOS DEWS III
Video Series from World Council of Optometry and Alcon Summarizes TFOS DEWS III

The World Council of Optometry (WCO) and Alcon have released a series of three videos to help eye care professionals understand and apply recommendations from the updated Dry Eye Workshop III (DEWS...

US FDA Signs Off on Special Protocol Assessment for Oculis’ Optic Neuritis Trial
US FDA Signs Off on Special Protocol Assessment for Oculis’ Optic Neuritis Trial

Swiss company Oculis announced May 7 that the US FDA had agreed to a special protocol assessment regarding PIONEER-1, a Phase III clinical trial evaluating Privosegtor for the treatment of optic ne...

Annual and Quarterly Ophthalmic Revenue Roundup for Santen, Carl Zeiss Meditec, Harrow, RxSight, ANI, and Lensar
Annual and Quarterly Ophthalmic Revenue Roundup for Santen, Carl Zeiss Meditec, Harrow, RxSight, ANI, and Lensar

Japan-based Santen reported May 12 that its revenue for its fiscal year 2025, which ended March 31, 2026, was JPY 291.6 billion ($1.8 billion, calculated for March 31, 2026), a 2.8 percent decline ...

Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the US
Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the US

Bausch + Lomb reported May 19 that it had launched its PreserVision AREDS3 eye vitamins in the US. The supplements add a unique B-vitamin complex to the AREDS2 nutrients recommended by the National...

Myopia Management Roundup: SightGlass, Hoya Tout Positive Results with Spectacle Lenses
Myopia Management Roundup: SightGlass, Hoya Tout Positive Results with Spectacle Lenses

SightGlass Vision reported May 6 that its DOT spectacle lenses for myopia control saved more than 1 diopter of progression on average after two years in a study of Chinese children ages 6 to 10. Th...

Portuguese Study of Luxturna Shows Functional Benefits, Structural Decline
Portuguese Study of Luxturna Shows Functional Benefits, Structural Decline

Luxturna (voretigene neparvovec) has demonstrated in clinical trials and real-world studies that it improves light sensitivity and functional vision, with a favorable safety profile. A new prospect...

Curative to Advance Metformin Eye Drops in Cooperation with PennVet
Curative to Advance Metformin Eye Drops in Cooperation with PennVet

Curative Biotechnology announced May 7 that it had entered into a sponsored research agreement with the University of Pennsylvania’s School of Veterinary Medicine (PennVet) to support a canine stud...

AOA Honors Leaders in Optometry With 2026 Annual Awards
AOA Honors Leaders in Optometry With 2026 Annual Awards

The American Optometric Association (AOA), the American Optometric Student Association, and the AOA Foundation have announced the recipients of the organizations’ 2026 annual awards. The winners ar...

2026-2027 Ophthalmic Meetings Calendar
2026-2027 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Generics, New Drug Classes, Sustained Release Dosing Shape Glaucoma Pharma Market
Generics, New Drug Classes, Sustained Release Dosing Shape Glaucoma Pharma Market

The glaucoma pharmaceuticals market is showing signs of emerging from its prolonged revenue slump. One cycle of conversions from proprietary drugs to generic drugs is nearing an end, and a new cycl...

Q1-2026 Ophthalmic Revenue Roundup for Tarsus, Sight Sciences, and Lenz
Q1-2026 Ophthalmic Revenue Roundup for Tarsus, Sight Sciences, and Lenz

Tarsus Pharmaceuticals, of Irvine, California, reported May 6 that its Q1-2026 revenue for Xdemvy was $145.4 million, an 85 percent increase over $78.3 million in Q1-2025. Xdemvy (lotilaner ophthal...

US FDA Commissioner Makary Resigns After Rocky Year in Top Job
US FDA Commissioner Makary Resigns After Rocky Year in Top Job

US FDA Commissioner Marty Makary, MD, MPH, resigned May 12 after a rocky year in the agency’s top job that saw mass layoffs, high-level resignations, and policy fights with lawmakers, drugmakers, a...

AMA Urges Physician Protections Against AI Deepfake Impersonation
AMA Urges Physician Protections Against AI Deepfake Impersonation

The American Medical Association (AMA) in April issued a policy framework that it says aims to combat the escalating risk of AI-manipulated images, videos, and audio that impersonate physicians. Th...

Mexico Approves Zeiss’ Artevo 850 OR Microscope and Micor 700 Cataract Handpiece
Mexico Approves Zeiss’ Artevo 850 OR Microscope and Micor 700 Cataract Handpiece

Carl Zeiss Meditec announced May 13 that regulators in Mexico had approved the Artevo 850 ophthalmic microscope and the Micor 700 cataract removal handpiece. The German company, with US headquarter...

IOP-Lowering Goggles Gain US FDA 510(k) Nod for Wireless Upgrade
IOP-Lowering Goggles Gain US FDA 510(k) Nod for Wireless Upgrade

Balance Ophthalmics announced May 12 that it had gained US FDA 510(k) clearance for a wireless-enabled, next-generation version of its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, design...

NeuroVision Acquires Durin Life Sciences to Advance Neurological Diagnostics
NeuroVision Acquires Durin Life Sciences to Advance Neurological Diagnostics

NeuroVision, the developer of Afina retinal imaging technology to detect neurodegenerative disease, announced May 12 that it had acquired Durin Life Sciences, of Stratford, New Jersey. No financial...

2026 ASCRS Meeting Adds Patriotic Pomp, Lighter Features to Program
2026 ASCRS Meeting Adds Patriotic Pomp, Lighter Features to Program

A wave of IOL launches dominated the 2026 meeting of the American Society of Cataract and Refractive Surgery (ASCRS), highlighting intensifying competition across the premium IOL space. But confere...

IOL Makers Go All in to Launch Premium Lenses at ASCRS Meeting
IOL Makers Go All in to Launch Premium Lenses at ASCRS Meeting

Johnson & Johnson Vision, BVI Medical, and Alcon showcased the strengths of their latest IOLs throughout the 2026 ASCRS meeting, explaining how their technology benefits the growing premium space. ...

Myopia Management Market Poised for Growth with Recent Product Advancements
Myopia Management Market Poised for Growth with Recent Product Advancements

Recent moves by eye care companies suggest that the myopia management market is entering a new phase. In September 2025, Essilor gained US marketing authorization for the Stellest, the first specta...

Bayer to Acquire Perfuse in Deal Worth Up to $2.45 Billion
Bayer to Acquire Perfuse in Deal Worth Up to $2.45 Billion

German drugmaker Bayer announced May 6 that it would acquire Perfuse Therapeutics in a deal worth up to $2.45 billion. Perfuse, of South San Francisco, California, is advancing PER-001 for glaucoma...

Revenio Group to Acquire Visionix in $341 Million Deal
Revenio Group to Acquire Visionix in $341 Million Deal

Finland’s Revenio Group, parent of ophthalmic diagnostic company iCare, announced April 13 that it would acquire France-based Visionix in a deal worth €290 million ($341 million). Revenio said that...

Select US FDA Approvals and Clearances in April 2026
Select US FDA Approvals and Clearances in April 2026

The US FDA’s ophthalmic device division granted clearance to four devices using the 510(k) pathway in April 2026, according to the agency’s database. Retmap received clearance for its RM Electrode,...

PDUFA Dates for Ophthalmic Drug Candidates
PDUFA Dates for Ophthalmic Drug Candidates

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026
US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026

The US Centers for Medicare and Medicaid Services (CMS) issued J-codes in Q1-2026 for Harrow’s Iopidine and Glaukos’ Epioxa and Epioxa HD. In addition, the CMS issued Q-codes for Zydec’s interchang...

Santen to Market Five of AbbVie’s Glaucoma Drops in Mainland China
Santen to Market Five of AbbVie’s Glaucoma Drops in Mainland China

Japan’s Santen Pharmaceutical announced April 17 that its China subsidiary had entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eye drops in the Chinese ma...

Viridian Leads Latest Fundraising with $250 Million in Public Offerings
Viridian Leads Latest Fundraising with $250 Million in Public Offerings

Viridian Therapeutics led recent ophthalmic fundraising efforts with $250 million in public offerings of convertible notes and Series B stock to advance its TED candidates. Financing announced in t...

Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe
Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb announced May 7 the European launch of the Bi-Blade+ dual-port vitrectomy cutter on the Stellaris Elite dual-function cataract and vitrectomy system. The Bi-Blade+ now offers 25 thous...

Glaukos Debuts Epioxa Epi-On Crosslinking at 2026 ASCRS Meeting
Glaukos Debuts Epioxa Epi-On Crosslinking at 2026 ASCRS Meeting

Glaukos launched Epioxa during the 2026 ASCRS meeting in April after announcing the product’s commercial availability in March. The company also shared plans to support access through patient assis...

Cellution Launches OptiCover Amniotic Graft at ASCRS Meeting
Cellution Launches OptiCover Amniotic Graft at ASCRS Meeting

Cellution Biologics launched its OptiCover amniotic graft for ocular use at the 2026 meeting of the American Society of Cataract and Refractive Surgery (ASCRS), which ran April 10-13 in Washington,...

Surgeons Share Experience With Three of Rayner’s Technologies
Surgeons Share Experience With Three of Rayner’s Technologies

Ophthalmologists took a deep dive into describing their experience with two of Rayner’s newest IOLs—the RayOne Galaxy and RayOne EMV Toric—along with the company’s Sophi phaco system at a Rayner-sp...

Emerging Companies Pursuing Ophthalmic Indications, May 2026
Emerging Companies Pursuing Ophthalmic Indications, May 2026

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Pioneering Eye Charities Team Up to Provide Cataract Surgery in Rwanda, Laos, Other Countries
Pioneering Eye Charities Team Up to Provide Cataract Surgery in Rwanda, Laos, Other Countries

Cure Blindness Project and The Fred Hollows Foundation reported April 2 that they are partnering to end avoidable blindness in Rwanda and Laos by 2035. In addition, they will address the cataract s...

Clinical Trial Updates for Ophthalmic Candidates, May 2026
Clinical Trial Updates for Ophthalmic Candidates, May 2026

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

New Tennessee Law Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy
New Tennessee Law Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy

Tennessee has become the 16th US state to pass a law expanding optometrists’ scope of practice to include in-office laser procedures. Senate Bill 2076, signed into law by Gov. Bill Lee on April 14,...

Inventors of Luxturna Win $3 Million Breakthrough Prize
Inventors of Luxturna Win $3 Million Breakthrough Prize

Penn Medicine’s Jean Bennett, MD, PhD, and Albert Maguire, MD, along with Katherine High, MD, of Children’s Hospital of Philadelphia (CHOP), have been awarded a prestigious Breakthrough Prize in Li...

Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells

Swiss scientists reported April 15 that they had developed a technology that can deliver healthy mitochondria directly to cells most affected by disease. They called their approach a major step tow...

Weekly Poll of MDs, US and Western Europe, May 2026
Weekly Poll of MDs, US and Western Europe, May 2026

May 2026 Ophthalmic News Briefs
May 2026 Ophthalmic News Briefs

Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...

Bayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 Billion
Bayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 Billion

German drugmaker Bayer announced May 6 that it would acquire Perfuse Therapeutics in a deal worth up to $2.45 billion. Perfuse, of South San Francisco, California, is advancing PER-001 for glaucoma...

Quarterly Ophthalmic Revenue Roundup for Alcon, Amgen, Hoya, Ocular Therapeutix, and Xbrane
Quarterly Ophthalmic Revenue Roundup for Alcon, Amgen, Hoya, Ocular Therapeutix, and Xbrane

Alcon reported May 6 that its Q1-2026 net sales were $2.69 billion, a 10 percent increase (+6 percent cc) over $2.45 billion in Q1-2025. Surgical net sales totaled $1.46 billion, consisting of $438...

Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe
Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb announced May 7 the European launch of the Bi-Blade+ dual-port vitrectomy cutter on the Stellaris Elite dual-function cataract and vitrectomy system. The Bi-Blade+ now offers 25 thous...

Xbrane Resubmits BLA to US FDA for Lucentis Biosimilar
Xbrane Resubmits BLA to US FDA for Lucentis Biosimilar

Sweden’s Xbrane Biopharma announced April 30 that it had resubmitted the biologics license application (BLA) for its Lucentis (ranibizumab) biosimilar to the US FDA. A complete response letter from...

Novelty Nobility Taps AGC Biologics to Help Advance Bispecific Retinal Candidate
Novelty Nobility Taps AGC Biologics to Help Advance Bispecific Retinal Candidate

South Korea’s Novelty Nobility announced May 4 that it had expanded its manufacturing agreement with AGC Biologics to advance retinal disease candidate NN4101 through process development and GMP ma...

Kubota Vision, Laboratoires Kôl Team Up on Compassionate Use of Stargardt Candidate
Kubota Vision, Laboratoires Kôl Team Up on Compassionate Use of Stargardt Candidate

Kubota Vision and Laboratoires Kôl announced May 4 that they had signed a supply and licensing agreement to bring emixustat hydrochloride, an oral treatment candidate for Stargardt disease, to pati...

US FDA Accepts Opus’ LCA5 Gene Therapy Candidate into New Rare Disease Program
US FDA Accepts Opus’ LCA5 Gene Therapy Candidate into New Rare Disease Program

Opus Genetics announced May 4 that the US FDA had accepted OPGx-LCA5, a gene therapy candidate targeting Leber congenital amaurosis type 5, into the new Rare Disease Evidence Principles (RDEP) prog...

BVI Announces Full CE Marking for its Virtuoso Platforms
BVI Announces Full CE Marking for its Virtuoso Platforms

BVI Medical reported April 20 that itsVirtuoso cataract-only and dual-function cataract-vitrectomy platforms had gained CE marking under the new European Union Medical Device Regulation (MDR). The ...

Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird
Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird

Bausch + Lomb reported April 29 that its Q1-2026 revenue was $1.24 billion, a 9 percent increase (+6 percent cc) over $1.14 billion in Q1-2025. Surgical segment revenue was $228 million, a 7 percen...

Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells

Swiss scientists reported April 15 that they had developed a technology that can deliver healthy mitochondria directly to cells most affected by disease. They called their approach a major step tow...

Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million
Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million

Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more